Open AccessCOVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges
Author(s) -
Gholam Reza Sivandzadeh,
Hasan Askari,
Ali Reza Safarpour,
Fardad Ejtehadi,
Ehsan Raeis-Abdollahi,
Armaghan Vaez Lari,
Mohammad Foad Abazari,
Firoozeh Tarkesh,
Kamran Bagheri Lankarani
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i22.6178
Subject(s) - medicine , covid-19 , liver injury , intensive care medicine , virology , pathology , disease , infectious disease (medical specialty) , outbreak
It is hypothesized that liver impairment caused by coronavirus disease 2019 (COVID-19) infection might play a central role in severe clinical presentations. Liver injury is closely associated with severe disease and, even with antiviral drugs, have a poor prognosis in COVID-19 patients. In addition to the common hepatobiliary disorders caused by COVID-19, patients with pre-existing liver diseases demand special considerations during the current pandemic. Thus, it is vital that upon clinical presentation, patients with concurrent pre-existing liver disease associated with metabolic dysfunction and COVID-19 be managed properly to prevent liver failure. Careful monitoring and early detection of liver damage through biomarkers after hospitalization for COVID-19 is underscored in all cases, particularly in those with pre-existing metabolic liver injury. The purpose of this study was to determine most recent evidence regarding causality, potential risk factors, and challenges, therapeutic options, and management of COVID-19 infection in vulnerable patients with pre-existing liver injury. This review aims to highlight the current frontier of COVID-19 infection and liver injury and the direction of liver injury in these patients.